RxDoctor Payments Data

Teresa Dietz

Family · Dillon, SCNPI 1538121991

Payments from drug & device makers

$2,737in general payments, 2019–2025

Across 150 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$686
  • Amgen$305
  • AbbVie$242
  • GSK$235
  • Biohaven Pharmaceuticals, Inc.$144
  • Abbott$123
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$2,72299%
  • Other$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,737 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$15,056
Medicare patients
58
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$18,236
Famotidine40$385
Gabapentin20$365
Duloxetine Hcl11$348
Cyclobenzaprine Hcl18$322
Rosuvastatin Calcium28$224
Fluticasone Propionate19$212
Omeprazole27$195
Losartan Potassium36$173
Atorvastatin Calcium25$167
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide12$159
Amlodipine Besylate26$141
Potassium Chloride15$131
Alprazolam18$130
Levothyroxine Sodium15$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$686$18,23616 claims
Almatica Pharma LLCSertraline Hcl$16$9123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Dillon

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →